High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram

High dosages of ceftriaxone are used to treat central nervous system (CNS) infections. Dosage adaptation according to the glomerular filtration rate is currently not recommended. Ceftriaxone pharmacokinetics (PK) was investigated by a population approach in patients enrolled in a French multicenter...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2019-09, Vol.63 (9), p.e00634-19
Main Authors: Grégoire, Matthieu, Dailly, Eric, Le Turnier, Paul, Garot, Denis, Guimard, Thomas, Bernard, Louis, Tattevin, Pierre, Vandamme, Yves-Marie, Hoff, Jérôme, Lemaitre, Florian, Verdier, Marie-Clémence, Deslandes, Guillaume, Bellouard, Ronan, Sébille, Véronique, Chiffoleau, Anne, Boutoille, David, Navas, Dominique, Asseray, Nathalie
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents
Ceftriaxone
Human health and pathology
Infectious diseases
Life Sciences
Meningitis, Bacterial
Nomograms
Pharmaceutical sciences
Pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High dosages of ceftriaxone are used to treat central nervous system (CNS) infections. Dosage adaptation according to the glomerular filtration rate is currently not recommended. Ceftriaxone pharmacokinetics (PK) was investigated by a population approach in patients enrolled in a French multicenter prospective cohort study who received high-dose ceftriaxone for CNS infection as recommended by French guidelines (75 to 100 mg/kg of body weight/day without an upper limit). Only those with suspected bacterial meningitis were included in the PK analysis. A population model was developed using Pmetrics. Based on this model, a dosing nomogram was developed, using the estimated glomerular filtration rate (eGFR) and total body weight as covariates to determine the optimal dosage allowing achievement of targeted plasma trough concentrations. Efficacy and toxicity endpoints were based on previous reports, as follows: total plasma ceftriaxone concentrations of ≥20 mg/liter in >90% of patients for efficacy and ≤100 mg/liter in >90% of patients for toxicity. Based on 153 included patients, a two-compartment model including eGFR and total body weight as covariates was developed. The median value of the unbound fraction was 7.57%, and the median value of the cerebral spinal fluid (CSF)/plasma ratio was 14.39%. A nomogram was developed according to a twice-daily regimen. High-dose ceftriaxone administration schemes, used to treat meningitis, should be adapted to the eGFR and weight, especially to avoid underdosing using current guidelines. (This study has been registered at ClinicalTrials.gov under identifier NCT01745679.).
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00634-19